European Respiratory Journal

Article	Citations
Soteria: deliverance from harm?	1302
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	1014
The right ventricle tamed	845
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	225
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	192
Chymase-1: a “MAST”-er switch in COPD?	189
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	178
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	174
Missing airways, ventilation defects and conductive airway physiology in asthma	163
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	162
A breath of the future: a novel human model for COPD and beyond	144
The lung that rules the heart	139
Randomised controlled trials utilisingFENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	131
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	127
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	125
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	117
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	115
Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD	115
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	110
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	109
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	108
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	107
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	107
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	101
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	101

Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	100
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	95
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	92
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomized controlled trial	89
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	88
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	86
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	84
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis	82
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	82
The environmental impact of inhaled therapy: making informed treatment choices	79
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	77
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	74
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	74
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	73
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	73
Treatment algorithm for pulmonary arterial hypertension	73
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	71
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	71
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	69
No exposure left behind: time to pay attention to children's chemical environment in lung development	68
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	67
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	65
WHO online guide on the use of digital technologies for tuberculosis programmes	65
The association between immunosuppressants and outcomes of COVID-19	63
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling	63
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	62
The limits of normal of pulmonary arterial wedge pressure	60
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	60
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	58
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	58
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	58
Pleural mesothelioma: surgery questioned again?	58
List ofEuropean Respiratory Journalpeer reviewers 2023	57
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?	57
FEV1Q: what (even) is normal lung function?	56
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander,et al.Eur Respir J2023; 62: 2300011.	56
The efficacy of singingversusexercise training: do the data really support the authors’ conclusions?	56
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	55
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis	55
The risk of hypoventilation during bronchoscopy under oxygen and procedural sedation	54
Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis	53
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	53
CPAP recall and cancer risk: should we be concerned?	53
Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety	51
Clinical, physiologic, imaging, and molecular responses to cannabis smoking: the Canadian Users of Cannabis Smoke (CANUCK) Study	50
Leukocytic ADAM10 and ADAM17 modulate disease severity and systemic outcome in bacterial and viral pneumonia	50
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study	50
Immunogenicity and safety of coadministration of COVID-19 and influenza vaccination	49
Prognostic phenotypes of early-stage lung adenocarcinoma	49
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	49

Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	49
Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study	48
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	48
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	48
Theratyping in cystic fibrosis: filling the knowledge gaps	47
Small extracellular vesicles and induction of epithelial-to-mesenchymal transition in lymphangioleiomyomatosis	46
Metabolomics in pulmonary medicine: extracting the most from your data	46
Reply to: Cause or consequence?	45
Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis	45
Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema	45
An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease	45
Early-life exposure to a mixture of phenols and respiratory health in preschool children	45
Cardiopulmonary response to exercise in adults born very preterm	44
Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis	44
Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease	44
Vocal cord paralysis as a rare complication of bronchoscopic lung volume reduction: a case series of five patients	44
Oral corticosteroids in asthma and beyond: moving forward	44
Muscle sympathetic nerve activity and adaptive servo-ventilation: questions remain	44
Bronchoconstriction with inhaled ATP in healthy volunteers	43
Liver cancer in severe alpha-1 antitrypsin deficiency: who is at risk?	43
ERJPodcast January 2024: The microbiome in early life and childhood asthma	42
Multitasking within the airway epithelium	42
COVID-19 changed the world – without changing CTEPH	42
ERJ Podcast October 2023: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma	40
Filters used for pulmonary function testing	40
Contributions to simplifying the global interpretation of spirometry: high quality spirometry data from Asia	40
Is tezepelumab more than just an anti-eosinophil drug?	39
Unbowed, unbent, unbroken: predicting pulmonary hypertension using echocardiography	39
The proteomic landscape of blood monocytes in community-acquired pneumonia	39
Prolonged higher dose methylprednisoloneversusconventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)	38
“Lung function trajectories in South African children with pulmonary tuberculosis compared to those with non-TB lower respiratory tract infection: a prospective study.” D.M. Gray, L. Githinji, K. Brit	38
Flavonoid intakes inversely associate with COPD in smokers	38
Heart rate response and cardiovascular risk during obstructive sleep apnoea: an easy biomarker derived from pulse oximetry	38
Right ventricular–pulmonary arterial coupling and its relationship to exercise haemodynamics in a continuum of patients with pulmonary vascular disease due to chronic thromboembolism	38
Indoor microbiome, microbial and plant metabolites, chemical compounds, and asthma symptoms in junior high school students: a multicentre association study in Malaysia	38
Treatment outcomes of multidrug-resistant tuberculosis with chronic kidney/liver disease	38
Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system	38
European Respiratory Society guidelines for the diagnosis of asthma in adults	37
European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases	37
Air pollution and COPD: GOLD 2023 committee report	37
MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study	36
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA	36
Transcriptomic clustering of critically ill COVID-19 patients	36
Risk assessment of systemic sclerosis-associated pulmonary arterial hypertension: cardiac indexversusstroke volume index	36
Epigenetic age among US adults with chronic respiratory diseases: results from NHANES 1999–2002	36
Moving the dial on identifying endotypes of asthma from early life	35
Presenting clinical data for the hazard classification of chemical respiratory sensitisers	35
Reply: The new ERS/ATS standards on lung function test interpretation: some extant limitations	35
What can lockdowns tell us about the underlying causes of asthma exacerbations? A retrospective cohort study	35
Spirometry forced expiratory time is driven by airflow limitation in asthmatic children	35
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension	35
Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: a cohort study in Belgium	35
Respiratory support and bronchopulmonary dysplasia in infants born at 22–26 weeks gestation in Sweden, 2004–2007 and 2014–2016	34
Reply to: Pirfenidone and lung cancer in idiopathic pulmonary fibrosis: mind the index date, detection bias and competing risks	34
Tracing the origins of fibrotic fibroblasts: does the name matter? Look at the genes!	34
Peripheral pulmonary artery stenosis in adults: a novel type of pulmonary vascular disease with a strong genetic background	34
Reducing the pressure in pulmonary arterial hypertension: sotatercept, haemodynamics and the right ventricle	34
ERJPodcast January 2025: Treatment response to mepolizumab in severe eosinophilic asthma	34
Pulmonary hypertension associated with left heart disease	33
Incidence of interstitial lung abnormalities: the MESA Lung Study	33
Dyspnoea in acutely ill mechanically ventilated adult patients: an ERS/ESICM statement	33
Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort	33
Pathogenic variants inCFAP46,CFAP54,CFAP74andCFAP221cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus	33
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studi	33
The longitudinal microbial and metabolic landscape of infant cystic fibrosis: the gut–lung axis	32
Evolving diagnostic techniques in mediastinal lymphadenopathy: is mediastinal cryobiopsy the new kid on the block?	32
Lung structure and longitudinal change in cardiac structure and function: the MESA COPD Study	32
I love you with all my lungs: a viewpoint on communicating effectively and positively about lung health	32
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud	32
Mechanical ventilation promotes lung tumour spread by modulation of cholesterol cell content	32
Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: a multicentre prospective study	32
Developing, validating, updating and judging the impact of prognostic models for respiratory diseases	31
The COVID-19 pandemic and pulmonary arterial hypertension in Italy: adaptation, outcomes and valuable lessons learned	31
Relieving dyspnoea through the brain	31
Decoding the eosinophil connection: implications for precision treatment of emphysematous in COPD	31
Combining digital adherence technology and therapeutic drug monitoring for personalised tuberculosis care	31
Technical standards for respiratory oscillometry and bronchodilator response cut-offs	31
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways	31
Airflow-based prediction of lateral wall collapse: advancing personalised hypoglossal nerve stimulation in obstructive sleep apnoea	31
Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL−1	31

Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or twoF508delalleles	30
The role of precision medicine in interstitial lung disease	30
Lung function during and after acute respiratory infection in COVID-19 positive and negative outpatients	30
Aspergillussensitisation: an underappreciated treatable trait in airway disease	30
Antigen identification and avoidance on outcomes in fibrotic hypersensitivity pneumonitis	30
Primary spontaneous pneumothorax: does size matter?	30
Now we know: chronic exposure to air pollutants is a risk factor for the development of idiopathic pulmonary fibrosis	30
Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series	30
A range of 30–62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance	30
How bad is your cough? The McMaster Cough Severity Questionnaire as a new tool to measure chronic cough	29
Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?	28
Ensuring availability of respiratory medicines in times of European drug shortages	28
Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?	28
All roads lead to COPD… or not?	28
Up-regulated matrix metalloproteinase activity in soil-transmitted helminth–tuberculosis co-infection is associated with increased lung pathology	28
Predicting asthma exacerbations: is there utility in noninvasive assessment of distal airway inflammation using multiple flowFENO?	28
“From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.” M.J. Divo, C. Liu, F. Polverino,et al.Eur Respir J2023; 62: 2300806.	28
Genetic associations between serotonin receptor 1F (HTR1F) regulatory variation and sleep apnoea in non-obese individuals: insights from GWAS and eQTL analyses	27
ERJPodcast December 2023: Year in review	27
The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma	27
NSAID-exacerbated respiratory disease, dupilumab and aspirin tolerance	27
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children	27
The identification of prevalent tuberculosis disease through infection screening among high-risk migrants in the Netherlands	27
ERJPodcast July 2023: The HISTORIC study	27
List ofEuropean Respiratory Journalpeer reviewers 2022	27
A European multi-center, randomized controlled trial of Pirfenidone in bronchiolitis obliterans syndrome after bilateral lung transplantation	27
Opioids for dyspnoea in interstitial lung disease: does the sequence and timing of therapy matter?	27
Nebulised liposomal amphotericin-B: a promising strategy for preventing ABPA relapse	27
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension	27
Decoding the complexity: mechanistic insights into comorbidities in idiopathic pulmonary fibrosis	26
An electrocardiogram-based AI algorithm for early detection of pulmonary hypertension	26
“Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.” Mark Toshner, Colin Church, Lars Harbaum,et al.Eur Respir	26
De novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnea of infancy	26
Extracorporeal life support as a bridge to lung transplantation strategy in anti-MDA5+ rapidly progressive interstitial lung disease is life-saving but with persistent difficulties at the bedside	26
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis	26
Tofacitinib in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a new standard of care emerges	25
Management of pulmonary hypertension in special conditions	25
Reply: SABRE for airway quantification in idiopathic pulmonary fibrosis: clarifications, limitations, and next steps	25
Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study	25
Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis	25
Integrating hot topics and implementation of treatable traits in asthma	25
Whole lung directed anti-muscarinic therapy improves small airway dysfunction in COPD patients	25
Gut microbiota-derived succinate aggravates acute lung injury after intestinal ischaemia/reperfusion in mice	25
Targeting AMPK and the Nrf2/HO-1 axis: a promising therapeutic strategy in acute lung injury	25
Multi-beat pressure volume loop-derived right ventricular-pulmonary arterial coupling predicts transplant-free survival in pulmonary arterial hypertension	25
Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: a double-blind, randomised, placebo-controlled trial	25
Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study	25
ERS statement on paediatric long-term noninvasive respiratory support	24
Progressive pulmonary fibrosis: an expert group consensus statement	24
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA)	24
Extracorporeal photopheresis for the prevention of rejection after lung transplantation: a prospective randomised controlled trial	24
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial	24
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia	24
Pulse oximeter measurements vary across ethnic groups: an observational study in patients with COVID-19	24
Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study	24
“Interstitial lung abnormalities are associated with decreased mean telomere length.” R.K. Putman, G.T. Axelsson, S.Y. Ash,et al.Eur Respir J2022; 60: 2101814	24
Uncovering early COPD? The T-slope as a novel CT biomarker for evaluating airway narrowing	23
The rat takes the cheese: a novel model of CFTR-dependent chronic bacterial airway infection	23
“Post tuberculosis”: the urgent need for inclusion of lung health outcomes in tuberculosis treatment trials	23
The interface in home non-invasive ventilation: is the nasal mask better?	23
Latent COPD: a proposed new term in the disease nomenclature	23
Comment on: Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case–control study in Sweden	23
TB or not TB: does AI have an answer for children?	23
Drug-induced lung disease: unwanted collateral damage	23
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis	23
Cancer risk associated with alpha-1-antitrypsin deficiency: only large registries will give us the answer	23
Heart or lungs? Why not both!	23
Right heart function during and after pregnancy in women with pulmonary arterial hypertension	23
Reversible carfilzomib-induced pulmonary arterial hypertension: don't take your eyes off the ball!	22
Deep phenotyping of unaffected carriers of pathogenicBMPR2variants screened for pulmonary arterial hypertension	22
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults	22
How do people with COPD walk? A European study on digitally measured real-world gait	22
“Spatial transcriptomics for respiratory research and medicine.” S. Curras-Alonso, J. Soulier, T. Walter, et al. Eur Respir J 2021; 58: 2004314	22
Building translational bridges in idiopathic pulmonary fibrosis research: from epithelial dysfunction to dysregulated macrophage polarisation and fibrogenesis	22
AMR-Lung: a European Clinical Research Collaboration on antimicrobial resistance in chronic lung disease	21
Genome-wide association study of susceptibility toPseudomonas aeruginosainfection in cystic fibrosis	21
Mycobacterium aviumcomplex genomics and transmission in a London hospital	21
The ERS PROFILE.net Clinical Research Collaboration is dedicated to the set-up of an academic network to enhance imaging-based management of progressive pulmonary fibrosis	21
MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease	21
Endothelial cells in pulmonary fibrosis: more than a bystander	21
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?	20
European Respiratory Society Clinical Practice Guideline for the Management of Adult Bronchiectasis	20
Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors	20
Sequential multimodal therapy in chronic thromboembolic pulmonary hypertension with mixed anatomical lesions: a proof of concept	20
Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic	20
Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis	20
Sfrp1 inhibits lung fibroblast invasion during transition to injury-induced myofibroblasts	20
Vulnerability to acid reflux of the airway epithelium in severe asthma	20
Increasing physical activity in severe asthma: a systematic review and meta-analysis	20
Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9%versus3%versus6% nebulised saline	20
Reply to: The puzzles surrounding the impact of face masks on 6-minute walking distance in pulmonary hypertension	19
Lung cancer in pulmonary fibrosis: no room for nihilism!	19
“Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats.” R. Dumitrascu, C. Kulcke, M. Königshoff,et al.Eur Respir J2011; 37: 1104–1118.	19
Comparison of oronasal and nasal masks in home mechanical ventilation: an observational cohort and bench study	19
ERJPodcast November 2023: Children and the ERS	19